Analysts expect Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report ($0.17) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from ($0.26) to ($0.12). Conatus Pharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which suggests a positive year over year growth rate of 51.4%. The firm is expected to issue its next quarterly earnings report on Wednesday, March 21st.
Zacks’ EPS calculations are an average based on a survey of research analysts that cover Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.08). The business had revenue of $9.57 million during the quarter, compared to the consensus estimate of $16.06 million. Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. During the same period in the prior year, the firm earned ($0.31) earnings per share.
Several analysts have weighed in on CNAT shares. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Stifel Nicolaus reissued a “buy” rating and issued a $10.00 price target on shares of Conatus Pharmaceuticals in a research note on Thursday, August 3rd. Seaport Global Securities reissued a “buy” rating and issued a $16.00 price target on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 price target (down from $18.00) on shares of Conatus Pharmaceuticals in a research note on Thursday, November 2nd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.00.
Conatus Pharmaceuticals (NASDAQ:CNAT) traded up $0.11 during trading on Friday, reaching $4.22. 288,033 shares of the company’s stock traded hands, compared to its average volume of 621,259. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.41. Conatus Pharmaceuticals has a 1-year low of $1.73 and a 1-year high of $9.40.
Several hedge funds have recently added to or reduced their stakes in CNAT. Bank of New York Mellon Corp increased its position in shares of Conatus Pharmaceuticals by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock valued at $464,000 after acquiring an additional 1,655 shares during the period. Renaissance Technologies LLC increased its position in shares of Conatus Pharmaceuticals by 28.1% in the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock valued at $1,358,000 after acquiring an additional 51,590 shares during the period. Bank of Montreal Can purchased a new position in shares of Conatus Pharmaceuticals in the second quarter valued at about $109,000. Russell Investments Group Ltd. purchased a new position in shares of Conatus Pharmaceuticals in the second quarter valued at about $679,000. Finally, Acadian Asset Management LLC increased its position in shares of Conatus Pharmaceuticals by 641.1% in the second quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock valued at $6,324,000 after acquiring an additional 949,785 shares during the period. Hedge funds and other institutional investors own 33.29% of the company’s stock.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.